Lobular Breast Cancer: Moon Shot Project

Daniel Francis Excerpts

Thursday 9th July 2026 Westminster Hall

[The Minister for Care (Stephen Kinnock)]

It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank the hon. Member for Horsham (John Milne) for securing this vital debate. I also thank the hon. Member for Maidstone and Malling (Helen Grant) for campaigning on this topic, following her own diagnosis of lobular breast cancer.

I add my tribute to Dr Susan Michaelis, as today marks one year since she passed away from lobular breast cancer. As a founder of the Lobular Moon Shot Project, she campaigned tirelessly on behalf of women diagnosed with lobular breast cancer and raised awareness for the condition. I also pay tribute to members of the Lobular Moon Shot Project, including Susan’s husband, Tristan Loraine, for picking up the mantle, continuing the important work of the project and carrying Susan’s torch forward.

I recognise the number of charities that carry out important work in this area, such as Lobular Breast Cancer UK, Breast Cancer Now and Cancer Research UK, and all the right hon. and hon. Members who continue to provide support, many of whom we have heard from today.

Lobular breast cancer accounts for 15% of breast cancer cases. However, as we have heard, this form of cancer sadly goes undetected in too many women. We are determined to transform diagnosis and outcomes for patients. Earlier this year, the Minister for Public Health and Prevention, who is the lead DHSC Minister on this issue—I am standing in for her today—and Lord Vallance, the Minister for Science, Innovation, Research and Nuclear at the Department for Science, Innovation and Technology, met representatives of the Lobular Moon Shoot Project. Alongside Government research funders, they discussed the Lobular Moon Shot’s work, listened to the experiences of lobular breast cancer from those who attended, and discussed how to advance research in this vital area.

Following that meeting, last month Lord Vallance hosted a scientific roundtable that brought together a range of researchers, clinicians and industry representatives to identify opportunities to advance research and innovation. At that meeting, attendees agreed that one of the next steps should be to encourage collaborative research and funding applications across multiple existing schemes, including for basic discovery science. I would like to emphasise that Government research funders stand ready to support that work as it progresses.

We acknowledge and share the Lobular Moon Shoot Project’s ambition for researchers to take a collaborative and interdisciplinary approach to addressing the unique challenges of lobular breast cancer. Government responsibility for delivering cancer research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research, and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation.

The Medical Research Council primarily supports the discovery sciences and fundamental biological research, which is the focus of the Lobular Moon Shot campaign. Through MRC, UKRI has emphasised its commitment to supporting interdisciplinary team-based research across its funding schemes and highlighted support for collaborative activities to provide a platform on which to build a portfolio of research in this important area. NIHR’s research is complementary to the MRC’s focus, supporting the translation of discovery science into patient benefit.

Through the MRC and NIHR, we are already funding research into lobular breast cancer. For example, a breast cancer screening study is investigating whether a new, faster MRI scan could detect breast cancers earlier. The FAST—first post-contrast subtracted—MRI is a new type of scan that aims to detect cancers, including lobular breast cancer, that may not be routinely picked up by mammograms during a first screening visit. The £1.36 million study is jointly funded by the MRC and the NIHR. Furthermore, with a total investment of £32 million, the Institute of Cancer Research and the Royal Marsden’s NIHR Biomedical Research Centre support lobular breast cancer by combining translational research, precision diagnostics and targeted clinical trials to develop and test tailored treatments.

Promising discoveries are being made. Scientists at the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research have recently discovered a drug, currently being tested in clinical trials for a rare blood cancer, that could also be used to treat lobular breast cancer. Researchers now hope to progress the drug to clinical trials for lobular breast cancer. More widely, we are supporting world-leading research and development to enable the prevention of cancer and to improve diagnosis, treatment and care for people affected by the conditions. Cancer is a major area of NIHR spending. Reflecting its high priority, the institute spent £141.6 million on it in 2024-25. Alongside that, UKRI invested £198 million in cancer research in the same year.

We are investing in the best science, which explores lobular breast cancer both in isolation and in conjunction with other cancers, to maximise the opportunity to share learning and identify possible breakthroughs. Historically, the breast cancer research community has categorised the field around signalling, pathway and molecular presentation on tumours. Rather than naming a particular cancer sub-type, therefore, grants within the MRC portfolio focus on the understanding of molecular mechanisms common to both lobular breast cancer and invasive breast cancer.

We know that more research is needed. That is why both the MRC and NIHR are committed to continuing to support the development of high-quality, fundable research proposals. There are a range of existing opportunities across funders that support this developing portfolio. The NIHR is actively encouraging high-quality, ambitious research proposals on lobular breast cancer, having launched a highlight notice in late 2025 to signal to researchers our interest in funding research into this area.

[Daniel Francis (Bexleyheath and Crayford) (Lab)]

rose—

[Helen Maguire]

rose—

[Stephen Kinnock]

I think my hon. Friend the Member for Bexleyheath and Crayford (Daniel Francis) was first.

[Daniel Francis]

I thank the hon. Member for Horsham (John Milne) for securing the debate. I have supported my constituent Emma Hunwick and her campaigning on this issue. It is the third time I have attended a debate on this subject in the two years I have been an MP. I hear what the Minister says about research, but I think what supporters want is assurance that we will not be having a similar conversation again next year. They want confidence that we will have made some progress in the next 12 months.

[Stephen Kinnock]

In a nutshell, what I am trying to lay out is that it is not an either/or question. There is a tremendous amount of work going on to research cancer, including lobular breast cancer, which is a vital subset of that work.

The challenge for us is the idea of ringfencing £20 million, because ringfencing is not the standard process. The standard process is to have applications that are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to the public and health and care services, value for money and scientific quality. If there is a difference of view in the Chamber today, it is whether we have an ecosystem of cutting-edge research, applications and competitive process, based on the principles I have just outlined, or a ringfenced fund.

I have to be absolutely clear and straight with my hon. Friend that currently the Government are not of the view that a ringfencing approach is the right way to go. The worry is that that approach could potentially cut across the ecosystem-based approach that we are seeking to nurture and foster, which we believe will deliver better outcomes in the end.